AK-138-D-1

N/A

Report date: 2026/05/11 20:01:57

Base Information

Drug NameAK-138-D-1
Drug Alias NameAK138D1AK-138-D-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsDNA topoisomerase I inhibitors
TargetsReceptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsSolid tumoursBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesZhongshan Akeso Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncZhongshan Akeso Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBreast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A